NIH R01 · 2025
PROJECT SUMMARY The long-term goal of this research is to change the prognosis of relapsed or refractory (r/r) T-cell Non-Hodgkin Lymphoma (T-NHL) using next-generation chimeric antigen receptor T-cell (CART) immunotherapy. CART therapy has led to remarkable clinical outcomes in B-cell malignancies, but the needle has not moved for most other cancers. Relapsed or refractory T-NHL are considered mostly incurable with available therapies and present a particular challenge for antigen-specific T-cell immunotherapy since normal and malignant T cells largely express the same surface antigens. Our group developed a novel approach to circumvent CART fratricide by deleting the pan T-cell antigen…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.